Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell
• Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Sage Therapeutics And Biogen Announces Submission Of A Single NDA Seeking Approval Of Zuranolone For The Treatment Of Both MDD And PPD
As previously announced, Sage Therapeutics, Inc. (the “Company”) began a rolling submission of a new drug application (an “NDA”) to the U.S. Food and Drug Administration (“FDA”) in
Sage Therapeutics And Biogen Announce Phase 3 SKYLARK Study Of Zuranolone In Postpartum Depression Met Its Primary And All Key Secondary Endpoints
Zuranolone 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints
Zuranolone 50 mg
Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Lowers Price Target to $53
Morgan Stanley analyst Vikram Purohit maintains Sage Therapeutics (NASDAQ:SAGE) with a Equal-Weight and lowers the price target from $57 to $53.
Sage Therapeutics: Q1 Earnings Insights
Sage Therapeutics (NASDAQ:SAGE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM.
Here's what investors need to know about the announcement.
Sage Therapeutics Q1 EPS $(2.07) Misses $(2.04) Estimate, Sales $1.58M Down From $1.58M YoY
Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.07) per share which missed the analyst consensus estimate of $(2.04) by 1.47 percent. This is a 26.22 percent decrease over losses of $(1.64) per share
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) have initiated a rolling submission of a marketing application to the FDA for zuranolone in…